With a December 31 deadline looming, European Commission President Ursula von der Leyen said Friday the bloc and Britain are making "better progress" in negotiating final Brexit issues that will lead to a trade deal.
"The upcoming G20 Summit this weekend could mark a new beginning for global cooperation", von der Leyen said in a statement.
Von der Leyen sounded optimistic about the movement, but realistic about the work still ahead in negotiations.
Von der Leyen said the Brussels-based commission will "hopefully soon" reach a vaccine-supply agreement with Moderna and is also in talks with Novavax Inc.
The European commission has sealed deals with several pharmaceutical companies including BioNTech and Pfizer to buy millions of doses of vaccines on behalf of all EU Member States.
"And if all proceeds with no problems. EMA tells us that the conditional marketing authorisation for BioNTech and Moderna could happen as early as the second half of December 2020".
Ugur Sahin, the director of BioNTech, said on Thursday there is the possibility that the jab will be distributed in the European Union and U.S. before 2021. Pfizer said its shot being developed with BioNTech was 95% effective in a final analysis of clinical-trial data and it's applying to the U.S. FDA for emergency-use authorization.
"We have all learned from our experience in the summer that the exit from a wave, in this case the exit from the first wave, is very hard and that the impact of lifting measures too hastily has had a very bad impact on the epidemiological situation in summer and fall", she said.
The twin breakthroughs have lifted hopes for an end to a pandemic that has infected more than 56 million people and caused more than 1.3 million deaths worldwide since the virus first emerged in China late a year ago.